Indication intelligence, analysis and sector perception

Biostage (BSTG) offering of 20 M common and 100% warrant coverage at $0.40

February 10, 2017 4:16pm

The offering was discounted from $0.50 and was completed at an overnight -$0.10 discount for gross proceeds of $8 M. BSTG closed at $0.30.

The offering was priced at $0.40 per share of common stock with each share of common stock sold with one five-year warrant to purchase one share of common stock, at an exercise price of $0.40 per share.

Rodman & Renshaw, a unit of H.C. Wainwright & Co., is acting as exclusive placement agent for the offering.

The Bottom Line: VERY UGLY but, it got done in a very BAD environment. The question will be … what will the company do to regain ANY value for shareholders in 2017; it will take a thorough review of the regulatory focus, the operational and scientific development and those associated with the company.

Biostage (BSTG) closed DOWN another -$0.206 to $0.30 after Thursday’s $0.50 (-$0.117) after Wednesday’s $0.62 (-$0.08), Tuesday’s $0.709 (-$0.0145), Monday’s $0.72 (+$0.04) and last Friday’s $0.68 (-$0.075).

The closing date of 2/15/17

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 45 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.